The therapeutic potential of mTOR inhibitors in breast cancer
作者： Linda S. Steelman , Alberto M. Martelli , Lucio Cocco , Massimo Libra , Ferdinando Nicoletti
DOI: 10.1111/BCP.12958
关键词:
摘要: … 4E-BP1. While rapamycin or the Akt inhibitor MK2206 solo treatment did not have significant effects on suppressing 4E-BP1 … Resveratrol is induced when the plant is attacked by …
sci-hub.se 参考文章(87)
Romain Baer, Célia Cintas, Nicole Therville, Julie Guillermet-Guibert, Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter? Advances in Biological Regulation. ,vol. 59, pp. 19- 35 ,(2015) , 10.1016/J.JBIOR.2015.05.001
Euphemia Y. Leung, Marjan Askarian-Amiri, Graeme J. Finlay, Gordon W. Rewcastle, Bruce C. Baguley, Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines PLOS ONE. ,vol. 10, ,(2015) , 10.1371/JOURNAL.PONE.0131400
Timothy L. Fitzgerald, Kvin Lertpiriyapong, Lucio Cocco, Alberto M. Martelli, Massimo Libra, Saverio Candido, Giuseppe Montalto, Melchiorre Cervello, Linda Steelman, Stephen L. Abrams, James A. McCubrey, Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells Advances in Biological Regulation. ,vol. 59, pp. 65- 81 ,(2015) , 10.1016/J.JBIOR.2015.06.003
Franco Lumachi, Davide A Santeufemia, Stefano MM Basso, Current medical treatment of estrogen receptor-positive breast cancer World Journal of Biological Chemistry. ,vol. 6, pp. 231- 239 ,(2015) , 10.4331/WJBC.V6.I3.231
Laura Brohée, Stéphane Demine, Jérome Willems, Thierry Arnould, Alain C. Colige, Christophe F. Deroanne, Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. Oncotarget. ,vol. 6, pp. 11264- 11280 ,(2015) , 10.18632/ONCOTARGET.3595
Wenting Mi, Qing Ye, Side Liu, Qing-Bai She, AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis Oncotarget. ,vol. 6, pp. 13962- 13977 ,(2015) , 10.18632/ONCOTARGET.3920
Olga V. Leontieva, Mikhail V. Blagosklonny, Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget. ,vol. 5, pp. 12715- 12727 ,(2014) , 10.18632/ONCOTARGET.3011
Filippo Montemurro, Giorgia Zucchini, Elena Geuna, Andrea Milani, Caterina Aversa, Rossella Martinello, Clinical utility of exemestane in the treatment of breast cancer International Journal of Women's Health. ,vol. 7, pp. 551- 563 ,(2015) , 10.2147/IJWH.S69475
Johanna C. Bendell, Robin K. Kelley, Kent C. Shih, Jennifer A. Grabowsky, Emily Bergsland, Suzanne Jones, Thomas Martin, Jeffrey R. Infante, Paul S. Mischel, Tomoo Matsutani, Shuichan Xu, Lilly Wong, Yong Liu, Xiaoling Wu, Deborah S. Mortensen, Rajesh Chopra, Kristen Hege, Pamela N. Munster, A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma Cancer. ,vol. 121, pp. 3481- 3490 ,(2015) , 10.1002/CNCR.29422
Mutsuko Yamamoto-Ibusuki, Monica Arnedos, Fabrice André, Targeted therapies for ER+/HER2- metastatic breast cancer BMC Medicine. ,vol. 13, pp. 137- 137 ,(2015) , 10.1186/S12916-015-0369-5